Antonioli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13:842–57.

Article  CAS  PubMed  Google Scholar 

Da M, Chen L, Enk A, Ring S, Mahnke K. The multifaceted actions of CD73 during development and suppressive actions of regulatory T cells. Front Immunol. 2022;13:914799.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mastelic-Gavillet B, Navarro Rodrigo B, Décombaz L, Wang H, Ercolano G, Ahmed R, et al. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. J Immunother Cancer. 2019;7:257.

Article  PubMed  PubMed Central  Google Scholar 

Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:709–24.

Article  CAS  PubMed  Google Scholar 

Yang R, Elsaadi S, Misund K, Abdollahi P, Vandsemb EN, Moen SH, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. J Immunother Cancer. 2020;8:e000610.

Article  PubMed  PubMed Central  Google Scholar 

Ray A, Song Y, Du T, Buon L, Tai YT, Chauhan D, Anderson KC. Identification and validation of ecto-5’ nucleotidase as an immunotherapeutic target in multiple myeloma. Blood Cancer J. 2022;12:50.

Article  PubMed  PubMed Central  Google Scholar 

Junttila MR, Ray A, Warne R, Chen XR, Du T, Lui F, et al. CD73 inhibition reverses immunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma. Blood. 2022;140:9957–8.

Article  Google Scholar 

Zavorotinskaya T, Blank B, Chan B, Chen C, Chen Y, Du X, et al. Abstract 1023: CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cells activation. Cancer Res. 2020;80:1023.

Article  Google Scholar 

Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol. 2018;29:1056–62.

Article  CAS  PubMed  Google Scholar 

Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012;106:130–7.

Article  CAS  PubMed  Google Scholar 

Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015;75:4494–503.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:3383–93.

Article  CAS  PubMed  Google Scholar 

Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.

Article  PubMed  Google Scholar 

Key Statistics About Multiple Myeloma. American Cancer Society (2021). https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html

Anderson KC. Promise of immune therapies in multiple myeloma. J Oncol Pract. 2018;14:411–3.

Article  PubMed  PubMed Central  Google Scholar 

Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16:309–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015;29:1441–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray A, Das DS, Song Y, Hideshima T, Tai YT, Chauhan D, et al. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2018;32:843–6.

Article  CAS  PubMed  Google Scholar 

Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21:4607–18.

Article  PubMed  PubMed Central  Google Scholar 

Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9:116.

Article  PubMed  PubMed Central  Google Scholar 

Busch A, Zeh D, Janzen V, Mügge LO, Wolf D, Fingerhut L, et al. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol. 2014;177:439–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burke B, Eden C, Perez C, Belshoff A, Hart S, Plaza-Rojas L, et al. Inhibition of histone deacetylase (HDAC) enhances checkpoint blockade efficacy by rendering bladder cancer cells visible for T cell-mediated destruction. Front Oncol. 2020;10:699.

Article  PubMed  PubMed Central  Google Scholar 

Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021;2:468–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chambers AM, Wang J, Lupo KB, Yu H, Atallah Lanman NM, Matosevic S. Adenosinergic signaling alters natural killer cell functional responses. Front Immunol. 2018;9:2533.

Article  PubMed  PubMed Central  Google Scholar 

Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019;27:2411–25.

Article  CAS  PubMed  Google Scholar 

Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, et al. Daratumumab in multiple myeloma. Cancer. 2019;125:2364–82.

Article  PubMed  Google Scholar